{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:04:34Z","timestamp":1783699474838,"version":"3.55.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, represents a new class of incretin-based therapy for type 2 diabetes mellitus (T2DM), obesity, and related comorbidities. This narrative review synthesizes evidence from the SURPASS, SURMOUNT, and SUMMIT clinical trial programs. Across studies, tirzepatide reduced glycated hemoglobin (HbA1c) by up to 2.5% and body weight by more than 20%. It also improved cardiovascular risk factors (blood pressure, lipids, inflammation) and has demonstrated benefits in patients with heart failure with preserved ejection fraction (HFpEF) and obstructive sleep apnea (OSA), with reductions in the apnea-hypopnea index (AHI) and heart failure hospitalizations. Its safety profile is consistent with that of GLP-1 receptor agonists (GLP-1 RAs), although gastrointestinal side effects, gallbladder events, and thyroid cancer signals warrant monitoring. Ethical concerns related to off-label use, weight regain after discontinuation, and barriers to real-world access remain active issues. Ongoing outcome trials and real-world data will clarify its long-term role and potential integration into future clinical guidelines.<\/jats:p>","DOI":"10.1097\/ms9.0000000000004055","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T16:00:27Z","timestamp":1762963227000},"page":"371-380","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A narrative review on tirzepatide\u2019s therapeutic potential in glycemic control and cardioprotection"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7780-9963","authenticated-orcid":false,"given":"Mrudula","family":"Thiriveedi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Decatur Morgan Hospital, Decatur, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Sto.","family":"Domingo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alabama College of Osteopathic Medicine, Dothan, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Yates","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alabama College of Osteopathic Medicine, Dothan, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Baddam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Huntsville Hospital, Huntsville, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik El","family":"Beblawy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Decatur Morgan Hospital, Decatur, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala","family":"Nimmana","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Huntsville Hospital, Huntsville, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Decatur Morgan Hospital, Decatur, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-015-0260-x","article-title":"Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes","volume":"14","author":"Paul","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"416\u201326","DOI":"10.2337\/dc17-1144","article-title":"The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study)","volume":"42","author":"Laiteerapong","year":"2019","journal-title":"Diabetes Care"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"863\u201373","DOI":"10.1007\/s13300-017-0280-5","article-title":"Achievement of glycated hemoglobin goals in the US remains unchanged through 2014","volume":"8","author":"Carls","year":"2017","journal-title":"Diabetes Therapy"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"1577\u201389","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"R5-20260514","first-page":"680\u201384","article-title":"The effectiveness and value of tirzepatide for type 2 diabetes mellitus","volume":"28","author":"Nikitin","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"R6-20260514","first-page":"7255\u201364","article-title":"Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review","volume":"86","author":"Joshi","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"879\u201388","DOI":"10.1093\/ajhp\/zxad080","article-title":"Tirzepatide: clinical review of the \u201ctwincretin\u201d injectable","volume":"80","author":"Krauss","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R9-20260514","doi-asserted-by":"crossref","first-page":"1193\u2013205","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"143\u201357","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"205\u201316","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"143\u201355","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"503\u201315","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"583\u201398","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"1811\u201324","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"534\u201345","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"613\u201326","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a randomized, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"2909\u201318","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"R19-20260514","first-page":"38\u201348","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"R20-20260514","doi-asserted-by":"crossref","first-page":"427\u201337","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"R21-20260514","first-page":"100082","article-title":"Transparency in the reporting of artificial intelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"1050\u201361","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the Treatment of Obesity: key Elements of the STEP trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"202\u201306","DOI":"10.31128\/AJGP-10-24-7432","article-title":"Bariatric surgery","volume":"54","author":"Shilton","year":"2025","journal-title":"Aust J Gen Pract"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"101636","DOI":"10.1016\/j.diabet.2025.101636","article-title":"Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States","volume":"51","author":"Hankosky","year":"2025","journal-title":"Diabetes Metab"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"319\u201328","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"1165\u201371","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"3766\u201378","DOI":"10.1111\/dom.15272","article-title":"Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials","volume":"25","author":"Kanbay","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R28-20260514","first-page":"348\u201359","article-title":"The effects of tirzepatide on lipid profile: a systematic review and meta-analysis of randomized controlled trials","volume":"33","author":"Mahar","year":"2024","journal-title":"J Obes Metab Syndr"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"591\u201398","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"544\u201351","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in HFpEF and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"R31-20260514","doi-asserted-by":"crossref","first-page":"699\u2013706","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R32-20260514","doi-asserted-by":"crossref","first-page":"1121387","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","volume":"14","author":"Meng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R33-20260514","doi-asserted-by":"crossref","first-page":"2671\u201378","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"R34-20260514","doi-asserted-by":"crossref","first-page":"22\u201333","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R35-20260514","doi-asserted-by":"crossref","first-page":"230624","DOI":"10.1155\/2012\/230624","article-title":"Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis","volume":"2012","author":"Sun","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"R36-20260514","doi-asserted-by":"crossref","first-page":"473\u201381","DOI":"10.1111\/dom.15333","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","volume":"26","author":"Patel","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R37-20260514","doi-asserted-by":"crossref","first-page":"227\u201338","DOI":"10.1007\/s40265-023-01992-4","article-title":"Tirzepatide: a Review in Type 2 Diabetes","volume":"84","author":"France","year":"2024","journal-title":"Drugs"},{"key":"R38-20260514","doi-asserted-by":"crossref","first-page":"1214334","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R39-20260514","doi-asserted-by":"crossref","first-page":"e70038","DOI":"10.1002\/edm2.70038","article-title":"Exploring connections between weight-loss medications and thyroid cancer: a look at the FDA adverse event reporting system database","volume":"8","author":"Abi Zeid Daou","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"R40-20260514","doi-asserted-by":"crossref","first-page":"17\u201328","DOI":"10.1007\/s40261-021-01110-w","article-title":"Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"42","author":"Wang","year":"2022","journal-title":"Clin Drug Investig"},{"key":"R41-20260514","doi-asserted-by":"crossref","first-page":"2069\u201376","DOI":"10.1007\/s00125-025-06466-8","article-title":"Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study","volume":"68","author":"Buckley","year":"2025","journal-title":"Diabetologia"},{"key":"R42-20260514","doi-asserted-by":"crossref","first-page":"488\u201395","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"R43-20260514","doi-asserted-by":"crossref","first-page":"1\u201311","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and ASCVD: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"key":"R44-20260514","doi-asserted-by":"crossref","first-page":"299\u2013310","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"R45-20260514","doi-asserted-by":"crossref","first-page":"1090\u2013104","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R46-20260514","doi-asserted-by":"crossref","first-page":"430\u201336","DOI":"10.2337\/dc24-1773","article-title":"Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post Hoc analysis from the randomized active- and placebo-controlled SURPASS-1-5 clinical trials","volume":"48","author":"Apperloo","year":"2025","journal-title":"Diabetes Care"},{"key":"R48-20260514","doi-asserted-by":"crossref","first-page":"12\u201322","DOI":"10.3803\/EnM.2024.1942","article-title":"The road towards triple agonists: glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor - an update","volume":"39","author":"Jakubowska","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R49-20260514","doi-asserted-by":"crossref","first-page":"e245586","DOI":"10.1001\/jamahealthforum.2024.5586","article-title":"Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"R50-20260514","first-page":"100455","article-title":"Achieving equitable access to incretin-based therapies in cardiovascular care","volume":"46","author":"Reddy","year":"2024","journal-title":"Am Heart J Plus"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:05:40Z","timestamp":1778749540000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004055","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"2025-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}